Modulation of TIM-3 expression on NK and T cell subsets in HIV immunological non-responders

Copyright © 2014 Elsevier Inc. All rights reserved.

Détails bibliographiques
Publié dans:Clinical immunology (Orlando, Fla.). - 1999. - 156(2015), 1 vom: 30. Jan., Seite 28-35
Auteur principal: de Kivit, Sander (Auteur)
Autres auteurs: Lempsink, Ludwijn J R, Plants, Jill, Martinson, Jeffrey, Keshavarzian, Ali, Landay, Alan L
Format: Article en ligne
Langue:English
Publié: 2015
Accès à la collection:Clinical immunology (Orlando, Fla.)
Sujets:Journal Article Research Support, Non-U.S. Gov't CD4(+) T cell Galectin-9 HIV Immunological non-responders NK cells TIM-3 Galectins HAVCR2 protein, human plus... Hepatitis A Virus Cellular Receptor 2 LGALS9 protein, human Membrane Proteins
Description
Résumé:Copyright © 2014 Elsevier Inc. All rights reserved.
Highly active antiretroviral therapy (HAART) for the treatment of HIV infection sustains viral suppression and increases CD4(+) T cells in HIV patients. However, in 10-25% of subjects, known as immunological non-responders (INRs), HAART does not increase CD4 count. We investigated a potential role for galectin-9 and TIM-3 in INRs as galectin-9 and TIM-3 have been described to modulate NK and T cell function. PBMCs were isolated from healthy controls, HIV immunological responders (IRs, >350CD4(+) cells/mm(3)) and HIV INRs (<350CD4(+) cells/mm(3)) and TIM-3 and galectin-9 expressions on NK cell subsets and CD4(+) T cells were assessed. HIV INRs and HIV IRs showed increased galectin-9 expression on CD16(-)CD56(bright) and CD16(+)CD56(+) NK cells and CD4(+) T cells. Only HIV INRs showed a reduced frequency of TIM-3-expressing CD16(+)CD56(+), CD16(+)CD56(-) and CD4(+) cells, which correlated with low peripheral CD4 counts. These data suggest that TIM-3 expression may be characteristic for HIV INRs
Description:Date Completed 26.02.2015
Date Revised 25.11.2016
published: Print-Electronic
Citation Status MEDLINE
ISSN:1521-7035
DOI:10.1016/j.clim.2014.10.009